Drug Profile
Dolutegravir/lamivudine - GSK
Alternative Names: Dovato; DTG/3TC; Lamivudine/dolutegravirLatest Information Update: 10 Apr 2024
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK; ViiV Healthcare
- Class 3-ring heterocyclic compounds; Amides; Antiretrovirals; Deoxyribonucleosides; Dideoxynucleosides; Oxazines; Pyrimidine nucleosides; Small molecules
- Mechanism of Action HIV integrase inhibitors; Nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed HIV-1 infections
Most Recent Events
- 08 Apr 2024 Registration for HIV-1 infections (In adolescents, Treatment-naive, In adults, In the elderly) in USA (PO)
- 07 Aug 2023 ViiV Healthcare plans phase-III VOGUE trial for HIV-1 Infections (Treatment-naive) in November 2023 (PO) (NCT05979311),
- 19 Jul 2023 ViiV Healthcare initiates phase III trial for HIV-I infections (Treatment experienced) in USA (PO, Tablet) (NCT reference) (NCT05911360)